I did not miss your points or Mc's, especially the licensing opportunities that has been discussed here on and off over many months.
My thoughts are that a presentation to potential investors should be as positive and strong as it can be. To that extent, the best attributes of your product(s) are featured; for Anavex, that is, of course, 2-73.
Presently, 2-73 has progressed in the Alzheimer's trial farther than any other. Even though the number is small at 7 for the mono-therapy portion, Anavex was given the go-ahead by and approval of the FDA to include these seven in the trial. With the 26/31 week data, the 2-73's mono-therapy shows results far superior to those of the combo of 2-73 + D.
To me, that would have been the most positive and most exciting slide in deck. As I indicated before, why weren't those results presented?
That is why to me, the presentation was disappointing.
News 
Market Data 
Discover 
